NCT04842604 - Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2021

Primary Completion Date

December 2, 2022

Study Completion Date

December 2, 2022

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia

Interventions

DRUG

Glasdegib

25 mg or 100 mg tablet

DRUG

Azacitidine

100 mg/vial powder for 25 mg/mL suspension for injection

Trial Locations (18)

4032

Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Hematologia Tanszek, Debrecen

Debreceni Egyetem Klinikai Kozpont Belgyogyaszati Klinika, Debrecen

5020

Landeskrankenhaus Salzburg, Universitatsklinik fur Innere Medizin III der PMU, Salzburg

Uniklinikum Salzburg, Landeskrankenhaus Salzburg, Salzburg

14080

Instituto Nacional de Cancerología, México

44093

CHU de Nantes Hotel Dieu, Nantes

CHU de Nantes, Nantes

46026

Hospital Universitari i Politecnic La Fe, Valencia

60126

AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi, Clinica Di Ematologia, Torrette Di Ancona

SOD Farmacia-Dipt dei servizi -AOU Ospedali Riuniti Umberto I, G.M. Lancisi, G. Salesi, Torette Di Ancona

R3A 1R9

Health Sciences Centre, Winnipeg

R3E 0V9

CancerCare Manitoba, Winnipeg

708 52

Ustavni lekarna, Ostrava - Poruba

Klinika hematoonkologie, Ostrava-Poruba

910-1193

University of Fukui Hospital, Yoshida-gun

545-8586

Osaka City University Hospital, Osaka

93-513

WWCOiT im. M. Kopemlka w Lodzl, Lodz

SM2 5PT

The Royal Marsden NHS Foundation Trust, Sutton